No title
Importance Biological staging of Alzheimer disease (AD) can improve diagnostic accuracy and prognostic assessment. However, existing approaches often require invasive procedures and specialized infrastructure, limiting their routine clinical use. Objective To develop and validate a plasma-based biological staging model that closely mirrors an amyloid and tau positron emission tomography (PET)–base
